Carlos Eduardo Brandão Mello

Carlos Eduardo Brandão Mello

Auto-generated profile, based on publicly available information

Carlos Eduardo Brandão Mello

Universidade Federal do Estado do Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2023 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
CVCynthia Melissa Valerio
Cynthia Melissa Valerio
CVCristiane Villela-Nogueira
Cristiane Villela-Nogueira
CCCintia Cercato
Cintia Cercato
Fernando GerchmanFernando Gerchman
Fernando Gerchman
COClaudia Oliveira
Claudia Oliveira
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on [...] ABSTRACT Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on

19 May 2021 in International Journal of Hepatology
Verified
Journal Article
Open access
PDF file
JAJefferson Abrantes
Jefferson Abrantes
DTDaniel Simplicio Torres
Daniel Simplicio Torres
CBCarlos Eduardo Brandão-Mello
Carlos Eduardo Brandão-Mello
Several studies have proposed a link between chronic hepatitis C virus (HCV) infection and the development of cognitive disorders. However, the inclusion of confounding factors in their samples significantly limits the interpretation of the results. Therefore, here, we aimed to compare the neurophysiological and cognitive performance between patients with HCV infection and a control group after excluding other factors that may cause cognitive impairment. This cross-sectional, group-control, observational study was performed from September 12, 2014, to October 20, 2017. HCV-infected patients and healthy individuals between 18 and 77 years were considered eligible. The exclusion criteria included well-established causes of cognitive impairment, such as depression and cirrhosis. The participants were submitted to neuropsychological testing to evaluate global cognitive function (minimental), sustained attention, divided attention, selective attention, working memory, psychomotor speed, and executive function and to a neurophysiological evaluation using quantitative electroencephalograms and P300 cognitive evoked potentials. Among the 309 patients considered eligible for the study, we excluded 259 patients who had one or more characteristics from the preestablished exclusion criteria, 18 who did not undergo neuropsychological and neurophysiological testing, and five who exhibited depression. The final sample consisted of 27 patients each in the HCV and control groups. The groups did not differ in age, schooling, and sex. The patients in the HCV group exhibited poorer performances in the cognitive areas involving attention ( ), memory ( ), and psychomotor velocity ( ) apart from exhibiting prolonged latency in the P3b component ( ) and score ( ) of the P300 evoked cognitive potential. In this study performed with strict selection criteria, on conducting neuropsychological and neurophysiological evaluations, we detected the presence of cognitive impairment characterized by the involvement of attention, working memory, psychomotor processing speed, and memory in the HCV group.

1 January 2022
Verified
Book Chapter
Closed access
MFM. K. Fakoury
M. K. Fakoury
CXC. C. V. Ximenes
C. C. V. Ximenes
MPM. A. Pires
M. A. Pires
AFA. Carmo Filho
A. Carmo Filho
ABA. M. A. Brito
A. M. A. Brito
CMC. E. B. Mello
C. E. B. Mello

28 September 2021 in Revista de Pesquisa Cuidado é Fundamental Online
Verified
Journal Article
Open access
PDF file
MFMax Kopti Fakoury
Max Kopti Fakoury
CXCatherine Da Cal Valdez Ximenes
Catherine Da Cal Valdez Ximenes
MPMarcia Amendola Pires
Marcia Amendola Pires
ACAureo Carmo
Aureo Carmo
ABAlan Messala A. Brito
Alan Messala A. Brito
CMCarlos Eduardo Brandão Mello
Carlos Eduardo Brandão Mello
Objetivos: descrever a frequência de depressão em pacientes com hepatite C (HCV) e relacionar com as variáveis biológicas e função hepática. Métodos: estudo transversal, descritivo, de abordagem quantitativa, que avaliou a depressão utilizando os critérios do Manual de diagnóstico e estatístico de transtornos mentais (DSM-V) e a associação com as variáveis biológicas e de função hepática em 85 pacientes com HCV crônica indicados para a terapia antiviral de ação direta (DAA) entre maio de 2018 e 2019. Resultados: detectou-se depressão em 47,1% dos pacientes, predominantemente depressão leve (95%). Entretanto a depressão ocorreu de forma independente das características biológicas, como sexo, idade, escolaridade, comorbidades associadas e da função hepática, como grau de fibrose e genótipo viral. Conclusões: a frequência de depressão foi alta em pacientes com HCV e não teve relação estatística com as características biológicas e função hepática, sugerindo a busca ativa da depressão como estratégia na condução destes pacientes.

8 July 2026 in Crohn's & Colitis 360
Verified
Journal Article
Open access
APANDREZA MAIA PEREIRA
ANDREZA MAIA PEREIRA
JSJuliana SCHMIDT
Juliana SCHMIDT
CMCarlos Eduardo Brandão Mello
Carlos Eduardo Brandão Mello
GSGuilherme Janeiro Schmidt
Guilherme Janeiro Schmidt
YTYolanda Faia Manhães Tolentino
Yolanda Faia Manhães Tolentino
SSSergio Luis Schmidt
Sergio Luis Schmidt
Background: Behavioral and cognitive manifestations have been increasingly recognized in Crohn disease (CD), yet the specific behavioral domains associated with clinical activity remain incompletely characterized. Although reduced response speed has been proposed as a key feature, moment-to-moment fluctuations in performance may better capture behavioral instability related to systemic inflammation. We examined behavioral variability and attentional performance in CD and their relationship with clinical activity. Methods: In this case–control study, patients with CD of at least 1 year’s duration (n = 31) and healthy controls (n = 37) completed a short, computerized attention test assessing sustained-attention, focused-attention, inhibitory control, and processing speed. Group differences were evaluated using multivariate and univariate analyses of covariance. Binary logistic regression evaluated the discriminative ability of attentional measures, while correlations and regression analyses examined associations with disease activity measured by the Harvey-Bradshaw Index (HBI). Results: Fifty percent of patients with CD were in clinical remission. Compared with controls, patients with CD demonstrated significantly greater attentional variability and higher omission error rates, whereas mean response speed did not differ significantly. Within the CD cohort, sustained attention was significantly associated with disease activity and was the only subdomain predicting HBI scores. Patients in clinical remission continued to show impairments in sustained and focused attention compared with controls, whereas response speed was unaffected. Conclusion: CD is associated with selective alterations in attentional stability rather than generalized slowing. Attentional variability tracks clinical activity and remains detectable during remission, suggesting that sustained attention may represent a sensitive cognitive marker of ongoing disease impact.

1 January 2026 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
FCFelipe José Fernández Coimbra
Felipe José Fernández Coimbra
AGAndré Luís de Godoy
André Luís de Godoy
PFPaulo Henrique de Sousa Fernandes
Paulo Henrique de Sousa Fernandes
HNHeládio Feitosa Neto
Heládio Feitosa Neto
RPRodrigo Nascimento Pinheiro
Rodrigo Nascimento Pinheiro
AOAlexandre Ferreira Oliveira
Alexandre Ferreira Oliveira
Background: Hepatocellular carcinoma is a leading cause of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and limited eligibility for curative therapies. Although major advances in systemic treatment and supportive care have occurred, clinical decision-making remains complex owing to inherent heterogeneity among patients with hepatocellular carcinoma. Aims: To record expert opinion on systemic treatment, response assessment, follow-up, and palliative care in hepatocellular carcinoma. Methods: A panel of 43 experts from multiple medical specialties developed clinically relevant questions addressing systemic therapy, response assessment, post-treatment follow-up, and palliative care. Results: Eighteen evidence-based recommendations were formulated, covering indications for systemic therapy across disease stages, selection of first- and second-line treatments, management of patients with impaired liver function, treatment-related toxicities, radiological response assessment, post-treatment surveillance, antiviral management after liver transplantation, and palliative care strategies for patients with advanced disease. Conclusions: This multidisciplinary consensus provides a comprehensive, clinically oriented framework for the management of hepatocellular carcinoma, with particular emphasis on systemic therapy, response assessment, follow-up strategies, and palliative care. Integrating scientific evidence with real-world considerations supports informed, patient-centered decision-making across diverse clinical scenarios.